The Glucosamine Study

The Glucosamine-Study

This study is currently recruiting patients.
Verified by Ullevaal University Hospital September 2006

Sponsored by: Ullevaal University Hospital
Information provided by: Ullevaal University Hospital
ClinicalTrials.gov Identifier: NCT00404079

clinical trials Purpose

Low back pain (LBP) is the most frequent cause of sick leave and disability pension, and degenerative and osteoarthritic (OA) changes is a significant cause of pain and disability. Some indications exist for symptomatic and possible cartilage-structure modifying effect on knee- and hip-osteoarthritis with glucosamine sulphate (GS). The OA process in the lumbar spine is most likely to OA processes in knees and hips, hence GS could have comparable symptomatic and structural effect on lumbar OA.

Study hypothesis: No difference in treatment effect exists between oral intake of GS- or placebo-capsules for patients with chronic low back pain measured with Roland Morris Disability Questionnaire.

Condition Intervention Phase
Low Back Pain
  Drug: Glucosamine sulphate
 Phase IV

MedlinePlus related topics:  Back Pain

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Official Title: Phase 4 Study of Glucosamine Sulphate in the Treatment for Chronic Low Back Pain Patients With Degenerative Lumbar MRI Findings

Further study details as provided by Ullevaal University Hospital:
Primary Outcome Measures: 
  • Roland Morris Disability Questionnaire

Secondary Outcome Measures: 
  • Visual Analogue Scale
  • EuroQol-5D

clinical trials Eligibility

Ages Eligible for Study:  25 Years and above,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria

Inclusion Criteria:

  • Low back pain for more than 6 months
  • Patient older than 25 years old
  • MRI findings comparable with lumbar degenerative/osteoarthritic changes.

Exclusion Criteria:

  • Spinal stenosis with neurological deficits
  • Spinal prolapse with neurological deficits
  • Rheumatoid arthritis, psoriatic arthritis,
  • Old lumbar fractures
  • Chronic pain syndromes (e.g. fibromyalgia)
  • Psychosocial status not suitable for participation
  • Pregnancy
  • Breastfeeding
  • Allergic to shellfish

clinical trials Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00404079

Philip Wilkens, M Chiro      004723016140    wiph@uus.no

Norway
      Ulleval Universtiy Hospital, Oslo,  0450,  Norway; Recruiting
Philip Wilkens, M Chiro  004723016140    wiph@uus.no 

Study chairs or principal investigators

Oliver Grundnes, MD,  Principal Investigator,  Ullevaal University Hospital   

clinical trials More Information

Study ID Numbers:  28130805
Last Updated:  April 20, 2007
Record first received:  November 23, 2006
ClinicalTrials.gov Identifier:  NCT00404079
Health Authority: Norway: Norwegian Medicines Agency
ClinicalTrials.gov processed this record on June 12, 2007
Last Updated: 06/19/2007
What is This?

Related Articles on this Topic